CROSS-DOMAIN PATTERN
Same drug, multiple disease domains
tocilizumab appears in hypotheses across 4 disease domains: Depression, Inflammatory bowel disease, Rheumatoid arthritis, Type 2 diabetes. Shared mediators that recur across at least two of those domains: C-reactive protein.
Aggregated from the catalog. Biological interpretation of any multi-indication mechanism would require independent validation — this is a structural observation only.
ALL HYPOTHESES
Repurposing candidates for tocilizumab
Depression 1
| Mediator | Outcome | Score | Tier | Lit. status | Trial | |
|---|---|---|---|---|---|---|
| IL-8 | major depressive disorder | 0.230 | Mid | partial evidence | active |
Inflammatory bowel disease 1
| Mediator | Outcome | Score | Tier | Lit. status | Trial | |
|---|---|---|---|---|---|---|
| C-reactive protein | Crohn's disease | 0.208 | Mid | reproduces known | none |
Rheumatoid arthritis 1
| Mediator | Outcome | Score | Tier | Lit. status | Trial | |
|---|---|---|---|---|---|---|
| STAT3 | prurigo nodularis | 0.208 | Mid | novel signal | none |
Type 2 diabetes 1
| Mediator | Outcome | Score | Tier | Lit. status | Trial | |
|---|---|---|---|---|---|---|
| C-reactive protein | type 2 diabetes | 0.230 | Mid | reproduces known | completed |